7 June 2017 - Deborah Wilkes
Archived
Germany's Grünenthal is acquiring the global rights to AstraZeneca's migraine treatment Zomig (zolmitriptan) in a deal worth up to USD302 million. The deal excludes the rights in Japan.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.